Vol 4, No 5 (October 2015): Translational Lung Cancer Research (Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care)

Preface on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care1

Lung cancer diagnostics and treatments 2015: a renaissance of patient care
Edward S. Kim

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care1

Lung cancer biomarkers, targeted therapies and clinical assays
Jai N. Patel, Jennifer L. Ersek, Edward S. Kim
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)
Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler
Treatment of advanced squamous cell carcinoma of the lung: a review
Benjamin A. Derman, Kathryn F. Mileham, Philip D. Bonomi, Marta Batus, Mary J. Fidler
Novel therapies in small cell lung cancer
Hirva Mamdani, Raghava Induru, Shadia I. Jalal
Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies
Charles B. Simone II, Stuart H. Burri, John H. Heinzerling
New strategies in immunotherapy for non-small cell lung cancer
Daniel R. Carrizosa, Kathryn A. Gold
Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin
Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance
Jeryl Villadolid, Jennifer L. Ersek, Mei Ka Fong, Lindsey Sirianno, Ellen S. Story
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer
Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Letter to the Editor

Response to “Is post-operative radiotherapy of any benefit after R0 resection for N2 disease?”
Cliff G. Robinson, Aalok P. Patel, Todd DeWees, Daniel Morgensztern, Jeffrey D. Bradley, Varun Puri

Disclosure:

1. The series “Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Edward S. Kim served as the unpaid Guest Editor for the series.

2. The series “Evidence-Based Medicine” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding.

3. The series “Controversies on Lung Cancer: Pros and Cons” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Suresh Senan and Helmut H. Popper served as the unpaid Guest Editors for the series.